Summary & Overview
CPT 0371U: Qlear UTI Multiplex Urine Molecular Test
CPT code 0371U identifies a Proprietary Laboratory Analyses (PLA) assay for Qlear UTI, a multiplex amplified-probe molecular test that detects one fungal and 16 bacterial organisms in urine specimens associated with urinary tract infections. As a PLA code, 0371U applies uniquely to the Qlear UTI test produced by Lifescan Labs of Illinois, Thermo Fisher Scientific. Its PLA status signals a single-source, manufacturer- or lab-specific service that is tracked separately from general molecular panels.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the clinical purpose of the test, typical site-of-service expectations, and the national relevance of PLA coding for proprietary diagnostics. The publication outlines billing and coverage considerations commonly affecting PLA codes, summarizes typical payer approaches, and provides context for coding fidelity and claim submission. Information on available benchmarks, payer policy variations, and related reimbursement trends is presented where available. Data not available in the input will be identified as such rather than inferred.
Billing Code Overview
CPT code 0371U is a Proprietary Laboratory Analyses (PLA) code specific to a single commercial test: Qlear UTI from Lifescan Labs of Illinois, Thermo Fisher Scientific. The code describes a laboratory assay that evaluates a urine specimen using a multiplex amplified probe technique to detect the presence of one fungal organism or any of 16 bacterial organisms that may cause urinary tract infections.
Service type: Laboratory — molecular diagnostic test
Typical site of service: Clinical laboratory or outpatient collection site (urine specimen collection with laboratory processing)
Clinical & Coding Specifications
Clinical Context
A 28-year-old female presents to an outpatient primary care clinic with dysuria, urinary frequency, and suprapubic discomfort for 48 hours after intermittent episodes of similar symptoms. A clean-catch urine specimen is collected and sent to the laboratory for molecular testing to identify bacterial or fungal pathogens causing urinary tract infection. The clinic uses the proprietary assay 0371U (Qlear UTI from Lifescan Labs of Illinois, Thermo Fisher Scientific), which applies a multiplex amplified probe technique to detect one fungal species and 16 bacterial organisms associated with UTI. The specimen is transported to the performing laboratory, processed on an automated platform, and results are returned electronically to the ordering clinician within the test’s turnaround time. Results guide selection of targeted antimicrobial therapy and influence decisions about urine culture, additional susceptibility testing, or referral to urology for complicated or recurrent infections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier required; default reporting | Use when no special circumstance applies to the service. |
26 | Professional component | Use when billing for only the professional component (interpretation) if separated from technical component. |
TC | Technical component | Use when billing for only the technical component (laboratory processing) if the performing lab bills separately. |
52 | Reduced services | Use if the test is partially performed or limited compared with full assay protocol. |
53 | Discontinued procedure | Use if specimen processing was started but the test was discontinued for clinical reasons. |
54 | Surgical care only (rare for labs) | Generally not applicable; included when organizational billing requires split of care. |
55 | Postoperative management only | Generally not applicable for this assay; may be used in complex care billing scenarios. |
62 | Two surgeons (not typical for lab) | Not typically used; included when facility billing systems list it for completeness. |
78 | Return to the operating room (related to prior procedure) | Not applicable to this lab test except in exceptional perioperative specimen handling. |
80 | Assistant surgeon | Not applicable to laboratory testing; included if billing system requires assistant reporting. |
82 | Assistant not available (when a qualified resident is not available) | Not applicable to this assay. |
QX | Ordering physician(s) modifier for financial relationships | Use when the ordering practitioner also performs a component subject to QX reporting per payer rules. |
QY | Ordering laboratory clinical diagnostic laboratory test (specimen pass-through) | Use when the test is performed by a qualified laboratory under the ordering laboratory’s billing arrangement. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Family Medicine | Primary care clinicians commonly order UTI molecular diagnostics. |
| 208D00000X | General Practice | Outpatient general practitioners order urine pathogen testing for symptomatic patients. |
| 207L00000X | Obstetrics & Gynecology | OB/GYN clinicians evaluate UTIs in female patients and order molecular assays. |
| 207K00000X | Internal Medicine | Internists manage adult UTIs and order diagnostic testing. |
| 207RH0000X | Emergency Medicine | Emergency clinicians may order rapid molecular UTI testing for acute presentations. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
N39.0 | Urinary tract infection, site not specified | Primary diagnosis prompting use of the 0371U molecular UTI panel to identify causative organisms. |
N30.00 | Acute cystitis without hematuria | Common presentation leading to urine testing with molecular detection for bacteria/fungi. |
N30.9 | Cystitis, unspecified | Clinical scenario where multiplex urine testing helps define pathogen presence. |
N10 | Acute pyelonephritis | More severe infection where rapid identification of organisms can direct therapy. |
N76.0 | Acute vaginitis | Symptoms may overlap with UTI; molecular testing can help differentiate causes when urine is tested. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
87086 | Culture, bacterial; urine, routine, with isolation and presumptive identification | Performed when culture is needed to obtain isolates for antimicrobial susceptibility after molecular detection. |
87088 | Culture, bacterial; urine, quantitative colony count, with isolation and presumptive identification | Used for quantitative assessment when colony counts guide management of complicated UTI. |
87471 | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | Example of molecular NAAT testing commonly performed alongside STI testing in genitourinary evaluations. |
87490 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms (e.g., multiplex panels), amplified probe technique, each organism | Represents molecular multiplex methodology similar in workflow to 0371U and may be used for comparison of methodology. |
81002 | Urinalysis, non-automated, without microscopy | Often performed at point of care and precedes molecular testing to assess pyuria or hematuria. |